Literature DB >> 2007642

Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment.

J R Hamilton1, A Noble, D W Denning, D A Stevens.   

Abstract

Cryptococcal antigen titers in 97 serum and 42 cerebrospinal fluid (CSF) specimens from 37 AIDS patients with culture-proven cryptococcal infection were determined with the Meridian kit (Meridian Diagnostics Inc., Cincinnati, Ohio) before and after treatment with pronase. The geometric mean titers before and after pronase treatment were 1:45 and 1:588 in serum and 1:97 and 1:79 in CSF, respectively. Only on serum (but not CSF) specimens after pronase treatment were (i) titers increased by 2 to 13 dilutions on 57% of the specimens, all of which had titers of less than or equal to 1:128 before pronase treatment, (ii) false-negative reactions on 27% of specimens before pronase treatment eliminated, all of which had titers from 1:4 to 1:4,096, (iii) prozone-like reactions (titer, less than or equal to 1:256) on 9% of the specimens before pronase treatment eliminated, and (iv) agglutination reactions on all specimens stronger and easier to interpret. Antifungal agents added to serum as well as freeze-thaw cycles did not change antigen titers in serum. After two separate tests, the same titers were obtained on 94% of 35 serum specimens that were treated with pronase and on 96% of 53 CSF specimens that were not treated with pronase. A total of 26 serum specimens and 28 CSF specimens from patients with no cryptococcal disease were negative before and after pronase treatment. The IBL kit (International Biological Labs Inc., Cranbury, N.J.) was compared with the Meridian kit on 41 serum specimens and 14 CSF specimens. Results from the two kits agreed on 54 and 68% of serum specimens and 86 and 93% of CSF specimens before and after pronase treatment, respectively. The IBL kit generally produced higher titers on specimens in disagreement and produced no prozone-like reactions. Routine pronase treatment of serum is recommended with the Meridian kit in order to eliminate false-negative and unclear agglutination reactions by producing a consistent interpretation of agglutination reactions. CSF specimens do not require pronase treatment. Titer results produced by the kits from the two different manufacturers varied considerably: the kits should not be used interchangeably for determining antigen titers in serum specimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007642      PMCID: PMC269763          DOI: 10.1128/jcm.29.2.333-339.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Corrected version specificity of the latex test for cryptococcal antigen: a rapid, simple method for eliminating interference factors.

Authors:  L Stockman; G D Roberts
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948

2.  Cryptococcal interstitial pneumonia: value of antigen determination.

Authors:  B D Fisher; D Armstrong
Journal:  N Engl J Med       Date:  1977-12-29       Impact factor: 91.245

3.  Experience with the use of pronase to eliminate interference factors in the latex agglutination test for cryptococcal antigen.

Authors:  L D Gray; G D Roberts
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

4.  Elimination of rheumatoid factor in the latex test for cryptococcosis.

Authors:  M A Gordon; E W Lapa
Journal:  Am J Clin Pathol       Date:  1974-04       Impact factor: 2.493

5.  Cryptococcal infections in patients with acquired immune deficiency syndrome.

Authors:  R H Eng; E Bishburg; S M Smith; R Kapila
Journal:  Am J Med       Date:  1986-07       Impact factor: 4.965

6.  Diagnosis of cryptococcal meningitis. Value of immunologic detection of cryptococcal antigen.

Authors:  J S Goodman; L Kaufman; M G Koenig
Journal:  N Engl J Med       Date:  1971-08-19       Impact factor: 91.245

7.  False positive latex tests for cryptococcal antigen in cerebrospinal fluid.

Authors:  R J Hay; D W Mackenzie
Journal:  J Clin Pathol       Date:  1982-02       Impact factor: 3.411

8.  False-negative cryptococcal antigen test.

Authors:  A M Stamm; S S Polt
Journal:  JAMA       Date:  1980-09-19       Impact factor: 56.272

9.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

Authors:  D W Denning; R M Tucker; L H Hanson; J R Hamilton; D A Stevens
Journal:  Arch Intern Med       Date:  1989-10

10.  Serum cryptococcal antigen determination in the presence of rheumatoid factor.

Authors:  R H Eng; A Person
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

View more
  20 in total

1.  Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum.

Authors:  Diane C McFadden; Oscar Zaragoza; Arturo Casadevall
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

2.  Development of a nested PCR for detection of Cryptococcus neoformans in cerebrospinal fluid.

Authors:  P Rappelli; R Are; G Casu; P L Fiori; P Cappuccinelli; A Aceti
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

3.  Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England.

Authors:  I A Hassan; P Critten; B Isalska; D W Denning
Journal:  J Clin Pathol       Date:  2006-07       Impact factor: 3.411

Review 4.  Microreview: capsule-associated genes of Cryptococcus neoformans.

Authors:  Ken Okabayashi; Atsuhiko Hasegawa; Toshi Watanabe
Journal:  Mycopathologia       Date:  2007-01       Impact factor: 2.574

5.  False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis.

Authors:  B P Currie; L F Freundlich; M A Soto; A Casadevall
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

6.  Evaluation of new monoclonal antibody-based latex agglutination test for detection of cryptococcal polysaccharide antigen in serum and cerebrospinal fluid.

Authors:  D L Kiska; D R Orkiszewski; D Howell; P H Gilligan
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

7.  Comparison of Antigen Detection and Nested PCR in CSF Samples of HIV Positive and Negative Patients with Suspected Cryptococcal Meningitis in a Tertiary Care Hospital.

Authors:  Sunita Kumari; Rajesh Kumar Verma; Dharmendra Prasad Singh; Ramakant Yadav
Journal:  J Clin Diagn Res       Date:  2016-04-01

8.  Utility of clinical assessment, imaging, and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis.

Authors:  Edward R Cachay; Joseph Caperna; Amy M Sitapati; Hamta Jafari; Sean Kandel; William C Mathews
Journal:  AIDS Res Ther       Date:  2010-08-03       Impact factor: 2.250

Review 9.  Asymptomatic cryptococcemia in resource-limited settings.

Authors:  Ana-Claire Meyer; Mark Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

10.  Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies.

Authors:  A Temstet; P Roux; J L Poirot; O Ronin; F Dromer
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.